MediciNova Reports Clinical Trial for Experimental ALS Drug is 50% Enrolled
Biopharmaceutical company MediciNova, Inc. recently completed enrollment of the first 30 patients with…
Articles by Margarida Azevedo, MSc
United Spinal Association Demands Wheelchair Accessible Taxicabs in DC for Those With ALS, Other Spinal Conditions
The national nonprofit United Spinal Association is advocating along with the Washington DC Taxicab Commission (DCTC) for the implementation of the DC…
Clinical Trial Will Explore Genetic identification of Familial and Sporadic Amyotrophic Lateral Sclerosis
Investigators at the Northwestern University Feinberg School of Medicine are currently enrolling participants for a clinical trial (ClinicalTrials.gov…
New App Uses ALS Patients with Speech Disabilities’ Own Voices to Help Them Communicate
The first app for amyotrophic lateral sclerosis (ALS) patients who have begun to lose their speaking abilities was recently launched…
Neuralstem Introduces Novel Therapies for ALS at BIO CEO & Investor Conference
Dual platform regenerative medicine company, Neuralstem, Inc., is wrapping up its participation in the …
First Contracting Human Muscle Grown in Duke University Lab, Could Provide Clues to ALS Treatment
A research group at Duke University accomplished a pioneering feat in laboratory synthesis. They were able to grow the world’s…
ALS Ice Bucket Challenge Funds its First Research Project in Canada
The ALS Society of Canada is proud to announce the first research project on amyotrophic lateral sclerosis (ALS) to receive funding…
ALS Gene Variant May Be Accelerating Disease in One-Third of Patients
A team of researchers from the Penn State College of Medicine found that a specific gene variant found in…
New Enzyme May Help Treat ALS By Modulating Inflammation
Researchers at The Scripps Research Institute in California found that a particular enzyme has a harmful ability to create inflammatory lipid…
Newron Pharma Enrolling Patients for Phase 2 Study on ALS Therapy
Newron Pharmaceuticals is about to initiate its Phase II clinical trial, designed to evaluate novel molecule sNN0029 in patients…